Superficial urinary bladder carcinoma

This study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…

This trial tests a gene therapy called FE 999326 (nadofaragene firadenovec) in Japanese patients with high-grade non-muscle invasive bladder cancer that has not responded to BCG treatment. The therapy is given as a liquid instilled into the bladder through a catheter every three …

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This study tests a drug called erdafitinib, placed directly into the bladder using a special delivery system, for people with non-muscle-invasive or muscle-invasive bladder cancer. The trial has four parts to find the best dose and check safety and effectiveness. About 235 partic…

This study looks at whether using ureteral stents (small tubes) after bladder cancer surgery leads to more or fewer problems than not using them. About 190 adults having their bladder removed will be randomly assigned to get stents or not. The main goal is to see who ends up back…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…

This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with non-muscle-invasive bladder cancer. The drug is injected directly into the tumor, sometimes with a laser. The main goal is to see if this approach is safe and feasible. About 55 pa…

This study tests an immunotherapy drug called camrelizumab, given directly into the bladder, for people with high-risk non-muscle invasive bladder cancer that did not respond to BCG treatment. The goal is to find a safe dose and see if it can prevent cancer from coming back or ge…

This study tests whether combining two immune-boosting drugs, pembrolizumab and BCG, can keep high-risk bladder cancer from coming back. About 45 people with early-stage but aggressive bladder cancer will receive this combination as their first treatment. The goal is to see if mo…

This study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…

This program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join…

This study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited …

This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk non-muscle invasive bladder cancer stay cancer-free longer. About 1,400 participants will receive either BCG alone or BCG plus pembrolizumab. The goal is to …

This was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…

This was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…